 SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 GLOBE NEWSWIRE -- Eliem Therapeutics, Inc. Nasdaq: ELYM, a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliems president and chief executive officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 3:00 PM ET. 